Shots:

• Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs PBO + CT demonstrated improvement in pathological complete response (pCR: 57.6% vs 41.1%) in early TNBC patients
• The P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel vs PBO + nab-paclitaxel- as a 1L treatment for patients with m-TNBC. Results: increment in 7.5mos. in median OS- no new safety concerns were identified with longer follow-up
• Lastly- the company presented P-III IMpassion131 study assessing Tecentriq + paclitaxel vs PBO + paclitaxel- as a 1L treatment for patients with m-TNBC. The study did not meet its 1EPs of PFS in the PD-L1+ population- OS data showed a negative trend

­ Ref: Roche | Image: Roche